IRIS
CARLOMAGNO, Chiara
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 6.041
NA - Nord America 5.489
EU - Europa 4.007
SA - Sud America 673
Continente sconosciuto - Info sul continente non disponibili 176
AF - Africa 148
OC - Oceania 5
Totale 16.539
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.231
SG - Singapore 2.581
RU - Federazione Russa 1.818
VN - Vietnam 1.184
CN - Cina 1.104
IT - Italia 693
HK - Hong Kong 563
BR - Brasile 510
NL - Olanda 265
DE - Germania 252
FR - Francia 191
FI - Finlandia 186
IE - Irlanda 158
CA - Canada 148
UA - Ucraina 128
GB - Regno Unito 109
BD - Bangladesh 107
IN - India 98
JP - Giappone 91
SE - Svezia 72
AR - Argentina 58
MX - Messico 54
ZA - Sudafrica 42
CI - Costa d'Avorio 40
PH - Filippine 37
KR - Corea 33
IQ - Iraq 31
ID - Indonesia 30
CO - Colombia 27
EC - Ecuador 27
PL - Polonia 24
TR - Turchia 22
AT - Austria 20
ES - Italia 20
TH - Thailandia 19
PK - Pakistan 17
CZ - Repubblica Ceca 15
TW - Taiwan 14
BE - Belgio 13
MY - Malesia 13
VE - Venezuela 13
SA - Arabia Saudita 12
MA - Marocco 11
CL - Cile 10
JO - Giordania 10
TN - Tunisia 10
CR - Costa Rica 9
NP - Nepal 9
PT - Portogallo 9
IR - Iran 8
LT - Lituania 8
PE - Perù 8
UY - Uruguay 8
BG - Bulgaria 7
EG - Egitto 7
KE - Kenya 7
PY - Paraguay 7
AZ - Azerbaigian 6
DO - Repubblica Dominicana 6
ET - Etiopia 6
PS - Palestinian Territory 6
UZ - Uzbekistan 6
AE - Emirati Arabi Uniti 5
IL - Israele 5
JM - Giamaica 5
PA - Panama 5
TT - Trinidad e Tobago 5
GT - Guatemala 4
HN - Honduras 4
LB - Libano 4
NI - Nicaragua 4
AL - Albania 3
BO - Bolivia 3
DZ - Algeria 3
EE - Estonia 3
EU - Europa 3
MN - Mongolia 3
OM - Oman 3
QA - Qatar 3
SY - Repubblica araba siriana 3
XK - ???statistics.table.value.countryCode.XK??? 3
AO - Angola 2
AU - Australia 2
BB - Barbados 2
BF - Burkina Faso 2
CG - Congo 2
CV - Capo Verde 2
GA - Gabon 2
GE - Georgia 2
GR - Grecia 2
HT - Haiti 2
KN - Saint Kitts e Nevis 2
KW - Kuwait 2
KZ - Kazakistan 2
LK - Sri Lanka 2
MK - Macedonia 2
NZ - Nuova Zelanda 2
RO - Romania 2
RS - Serbia 2
SK - Slovacchia (Repubblica Slovacca) 2
Totale 16.337
Salva come PNG Salva come JPEG
Città #
Singapore 1.235
San Jose 1.007
Hong Kong 545
Ashburn 517
Moscow 441
Beijing 367
Ho Chi Minh City 330
Chandler 325
Hanoi 280
Amsterdam 253
Santa Clara 221
Los Angeles 175
Millbury 171
Naples 142
Council Bluffs 141
The Dalles 126
Princeton 125
Lauterbourg 120
Munich 116
Nanjing 99
Napoli 92
Tokyo 78
Jacksonville 76
New York 76
Boston 66
Buffalo 61
Wilmington 60
Hefei 59
Dallas 54
Haiphong 54
São Paulo 52
Da Nang 50
Redondo Beach 47
Nanchang 43
Ottawa 42
Turku 42
Des Moines 41
Chicago 38
Jiaxing 31
Brooklyn 30
Houston 30
Mexico City 28
Tianjin 28
Frankfurt am Main 27
Phoenix 26
Atlanta 25
Montreal 25
Denver 24
Milan 24
Rome 24
Washington 24
Hải Dương 23
Orem 20
Toronto 20
Helsinki 19
Nuremberg 19
Seattle 19
Warsaw 19
Shenyang 18
Chennai 17
Ninh Bình 17
Biên Hòa 16
London 16
Lawrence 15
Manchester 15
San Francisco 15
Shanghai 15
Stockholm 15
Woodbridge 15
Poplar 14
Can Tho 13
Hebei 13
Johannesburg 13
Ann Arbor 12
Charlotte 12
Norwalk 12
Olomouc 12
Seoul 12
Changsha 11
Falkenstein 11
Indiana 11
Dublin 10
Falls Church 10
Kochi 10
Kunming 10
Mumbai 10
Thái Nguyên 10
Tân Tiến 10
Baghdad 9
Belo Horizonte 9
Brasília 9
Curitiba 9
Guayaquil 9
Jeddah 9
Kuala Lumpur 9
Lentini 9
Pune 9
Rio de Janeiro 9
Dong Ket 8
Guangzhou 8
Totale 8.748
Salva come PNG Salva come JPEG
Nome #
A case report of limbic encephalitis in a metastatic colon cancer patient during first-line bevacizumab-combined chemotherapy 242
Manuale di Oncologia Clinica 237
STATO DELL'ARTE SULLA CHEMIOTERAPIA NEL CANCRO DEL COLON 198
Prognostic role of sarcopenia in metastatic colorectal cancer patients during first-line chemotherapy: A retrospective study 188
FOLFIRI in patients with locally advanced or metastatic pancreatic or biliary tract carcinoma: a monoinstitutional experience 184
A specific miRNA signature correlates with complete pathological response to neoadjuvant chemo-radiotherapy in locally advanced rectal cancer 181
The impact of schedule on acute toxicity and dose-intensity of high-dose chemotherapy with epirubicin and cyclophosphamide plus colony stimulating factors in advanced breast cancer. 170
EGFR mutations detected on cytology samples by a centralized laboratory reliably predict response to gefitinib in non-small cell lung carcinoma patients. 169
Evaluation of exercise capacity by means of cardiopulmonary exercise testing (CPET) in older adult cancer patients undergoing antineoplastic treatments 166
Discordance in RAS mutations between primary colon tumor and metastases: a real event or a matter of methodology? 165
Fast Detection of a BRCA2 Large Genomic Duplication by Next Generation Sequencing as a Single Procedure: A Case Report. 165
Impact of a cardio-oncology unit on prevention of cardiovascular events in cancer patients 165
Addition of erlotinib to fluoropyrimidine-oxaliplatin-basedchemotherapy with or without bevacizumab: Two sequential phase I trials 160
Adjuvant treatment for locally advanced rectal cancer patients after pre-operative chemoradiotherapy: when, and for whom? 160
Prevention of cardiovascular complications in elderly cancer patients 160
Concomitant Interferon-alfa and chemotherapy in hepatitis C and colorectal cancer: a case report 159
Second-line chemotherapy with a hybrid-alternating regimen of bolus 5FU modulated by methotrexate and infusional 5FU modulated by folinic acid in patients with metastatic colorectal cancer pretreated with 5FU. A phase 2 study. 158
Primary hepatic lymphoma in a patient with previous rectal adenocarcinoma: a case report and discussion ofetiopathogenesis and diagnostic tools 153
UbcH10 expression can predict prognosis and sensitivity to the antineoplastic treatment for colorectal cancer patients 153
Risk factors for cancer-related venous thromboembolism in ambulatory patients. 151
Preventing Venous Thromboembolism in Ambulatory Cancer Patients: The ONKOTEV Study 151
Twenty-year results of the Naples GUN randomized trial: predictive factors of adjuvant tamoxifen efficacy in early breast cancer. 150
Role of sphingosine kinase 1 (SphK1) on cetuximab resistance in colorectal cancer models 150
Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trial 147
A phase I study of paclitaxel and epirubicin, without and with filgrastim, for the treatment of platinum-resistant advanced ovarian cancer. 145
Management of patients with BRCA1/2-associated breast cancer 145
Double complete response in MCRC patient 142
Adjuvant FOLFOX-4 in patients with radically resected gastric cancer: tolerability, and prognostic factors. 141
CMF vs alternating CMF/EV in the adjuvant treatment of operable breast cancer. A single centre randomised clinical trial (Naples GUN-3 study). 140
Weekly docetaxel and capecitabine is not effective in the treatment of advanced gastric cancer: a phase II study. 138
Core curriculum. Oncologia clinica 137
Prognostic role of postoperative persistence of ctDNA molecular signature after liver resection for colorectal liver metastases: Preliminary results from a prospective study 136
Modulation of 5-fluorouracil as adjuvant systemic chemotherapy in colorectal cancer: the IGCS-COL multicentre, randomised, phase III study. 136
MULTIDISCIPLINARY APPROACH TO PATIENTS WITH MALIGNANT MELANOMA 135
Neoadjuvant treatment with capecitabine and oxaliplatin in combination with radiotherapy for rectal cancer patients: a phase II study 134
Cytological diagnosis of thyroid nodules in Hashimoto thyroiditis in elderly patients 134
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as initial treatment for metastatic colorectal cancer (TRIBE study): updated survival results and final molecular subgroups analyses. 134
Genetic mutations in the treatment of anaplastic thyroid cancer: a systematic review 133
SANGER SEQUENCING IN ROUTINE KRAS TESTING: AREVIEW OF 1720 CASES FROM A PATHOLOGIST’SPERSPECTIVE 132
MULTIPLE PRIMARY MALIGNANT NEOPLASM AND FAMILIAR ANAMNESIS 131
High-rsolution melting analysis (HRMA) for KRAS mutatiinal study in patients with metastatic colorectal cancer (mCRC pts) 131
Vinorelbine + mitomycin C as second-line treatment of metastatic breast cancer: a two-stage phase 2 study. 130
The Epithelial-Stromal Interaction as a Potential Target for Breast Cancer Treatment 130
Analysis of differential miRNA expression in primary tumor and stroma of colorectal cancer patients 128
Poly(adenosine diphosphate-ribose) polymerase 1 expression in malignant melanomas from photoexposed areas of the head and neck region. 127
Phase I-II study of xelox and bevacizumab plus erlotinib in sequential combination (XELOX-TARAV) in first line colorectal cancer: run in part 126
MicroRNA profiling as predictive factor of complete pathological response to neoadjuvant chemoradiothetapy in patients with locally advanced cancer 126
A phase II study of beweekly oxaliplatin plus infusional 5fluorouracil and folinic acid (FOLFOX4) as first-line treatment of advenced gastric cancer patients 126
A Metanalysis on the Interaction between HER2 Expression and Response to Endocrine Treatment in Advanced Breast Cancer 125
FOLFOXIRI/bevacizumab (bev) versus FOLFIRI/bev as first-line treatment in unresectable metastatic colorectal cancer (mCRC) patients (pts): Results of the phase III TRIBE trial by GONO group. 125
A Post Hoc Analysis of Older Patients with Metastatic Colorectal Cancer Receiving Oxaliplatin-Based Chemotherapy Plus Bevacizumab: The Randomized Obelics Study 125
Bevacizumab maintenance in metastatic colorectal cancer: How long? 124
C-erbB2 overexpression decreases the benefit of adiuvant tamoxifen in early breast cancer without axillary lymph node metastases. 123
Bevacizumab as 4th line treatment in metastatic colorectal cancer 123
Core curriculum. Oncologia clinica 123
Surgery in lung cancer metastasis 122
Molecules and mechanisms to overcome oxidative stress inducing cardiovascular disease in cancer patients 122
KRAS testing in metastatic colorectal carcinoma: challenges, controversies, breakthroughs, and beyond 121
Less frequently mutated genes in colorectal cancer: Evidences from next-generation sequencing of 653 routine cases 120
Multiple treatment lines and prognosis in metastatic colorectal cancer patients 119
Bevacizumab-induced hypertension is a predictive marker of response and progression free survival in patients treated for metastatic colorectal cancer 118
A prognostic model comprising pT stage, N status, and the chemokine receptors CXCR4 and CXCR7 powerfully predicts outcome in neoadjuvant resistant rectal cancer patients. 118
Bevacizumab related arterial hypertension as a predictive marker in metastatic Colorectal Cancer (mCRC) patients 117
KRAS mutation detection by high resolution melting analysis significantly predicts clinical benefit of cetuximab in metastatic colorectal cancer 117
Sphingosine Kinase 1 (SphK1) overespression contributes to cetuximab resistance in human colrectal cancer. 117
Measurement of neovascularization is an independent prognosticator of survival in node-negative breast cancer patients with long-lerm follow-up. 116
Prolactin receptor does not correlate with oestrogen and progesterone receptors in primary breast cancer and lacks prognostic significance. Ten year results of the Naples adjuvant (GUN) study. 116
Identification of a novel truncating mutation in PALB2 gene by a multigene sequencing panel for mutational screening of breast cancer risk-associated and related genes 116
A randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in the treatment of patients with metastatic colorectal cancer-OBELICS (Optimization of BEvacizumab scheduLIng within Chemotherapy Scheme) 115
Cardio-Oncology Challenges in Elderly Patients 114
Dihydropyrimidine dehydrogenase polymorphisms in patients with gastrointestinal malignancies and their impact on fluoropyrimidine tolerability: Experience from a single Italian institution 114
Raltitrexed versus standard leucovorin-modulated 5Fluorouracil: results form the randomized phase III Pan-European Trial in Adjuvant Colon Cancer 01 (PETACC-1). 114
Correlation between bevacizumab-related hypertension and response in mCRC patients 114
Forearm cutaneous metastasis of rectal adenocarcinoma: a case report 113
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. 112
Prognostic significance of necrosis, elestosis, fibrosis and inflammatory cell reaction in operable breast cancer. 112
HER2 as predictive marker of resistance to endocrine treatment for advanced bresat cancer: a metanalysis of published studies 111
Chemotherapy with mitomycin C and vinblastine in pretreated metastatic breast cancer. 109
Altri tumori gastrointestinali 108
Cancro del colon-retto 107
Mitomycin C and mitoxantrone in anthracycline-pretreated advanced breast cancer patients. A phase II study. 104
FOLFOXIRI plus bevacizumab (bev) versus FOLFIRI plus bev as first-line treatment of metastatic coloectal cancer (MCRC): results of the phase III tandomized TRIBE trial 103
Prognostic significance of multifocality in primary breast cancer. 102
Two novel sequence variants in MSH2 gene in a patient who underwent cancer genetic counseling for a very early-onset epithelial ovarian cancer 102
Endocrine factors in the outcome of systemic adjuvant therapy of early breast cancer. 101
A predictive index of axillary nodal involvement in operable breast cancer. 101
Metastasis of colon cancer to the thyroid gland: a case diagnosed on fine-needle aspirate by a combined cytological, immunocytochemical and molecular approach. 101
Adjuvant chemoendocrine therapy for early breast cancer: is it worthwhile? 100
Beyond KRAS: Predictive factors of the efficacy of anti-EGFR monoclonal antibodies in the treatment of metastatic colorectal cancer 100
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. 99
Skin lesions: unusual presentation of gastric cancer 95
Unusual case of exacerbation of sub-acute descending necrotizing mediastinitis 95
Predictive factors of complete response to neoadjuvant chemoradiotherapy in patients with rectal cancer 93
DNA-flow cytometry (ploidy and S-phase fraction) as prognostic factor in a retrospectine series of 515 primary breast cancer. 91
KRAS Mutant Allele Specific Imbalance (MASI) assessment in routine samples of metastatic colorectal cancer patients 91
microRNA come parametri predittivi di risposta ai farmaci a bersaglio molecolare specifico nelle neoplasie del colon-retto 89
Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. 88
Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial 88
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. 87
Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. 87
Totale 12.966
Salva come PNG Salva come JPEG
Categoria #
all - tutte 54.603
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 54.603
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022813 0 0 5 7 1 26 7 43 165 76 159 324
2022/2023999 144 59 26 50 94 85 6 89 152 238 40 16
2023/2024619 29 88 75 58 28 75 11 74 4 5 110 62
2024/20254.029 187 241 14 36 106 173 423 211 370 443 1.499 326
2025/20268.019 828 454 737 675 1.376 334 1.125 400 1.061 587 219 223
2026/2027723 184 296 243 0 0 0 0 0 0 0 0 0
Totale 16.539